Właściwości przeciwbólowe melatoniny oraz jej możliwości terapeutycznego zastosowania w zespołach bólowych

• Autorzy: Zan R.S. , Rolinski Z. , Kowalski C. J. , Burmanczuk A.

Warianty tytułu

EN

Analgesic properties of melatonin and its possible therapeutic application in pain syndromes

• Języki publikacji: PL

Abstrakty

EN

The aim of this paper was to analyze the role of melatonin (MLT) in acute and chronic pain states, and to describe the profile of melatonin as a potential analgesic. Melatonin (N-acetyl-5-methoxytryptamine) is the main pineal neurohormone involved in many physiological and endocrine functions, as well as in behavioral states in humans and animals. One may mention functions such as the regulation of circadian rhythm, sleep, mood, processes of reproduction, immune response, and aging. The distribution of MLT receptors in the spinal cord and in many other regions of the brain associated with receiving pain impulses, indirectly confirms the possible involvement of indoleamine in the phenomenon of pain. In clinical studies, MLT has been shown to have analgesic benefits in patients with acute and chronic pain (migraine, fibromyalgia, irritable bowel syndrome). In preliminary studies, it has also been suggested that MLT may have potent analgesic and anxiolytic properties in the perioperative period.

Słowa kluczowe

PL

bol; zwalczanie bolu; melatonina; wlasciwosci przeciwbolowe; zastosowanie; mechanizm dzialania; badania eksperymentalne; badania kliniczne; dzialanie przeciwbolowe

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2014
• Tom: 70
• Numer: 06
• Opis fizyczny: s.336-341,bibliogr.

Twórcy

autor

Zan R.S.

• Zakład Farmakologii, Katedra Przedklinicznych Nauk Weterynaryjnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, u.Akademicka12, 20-033 Lublin

autor

Rolinski Z.

• Zakład Farmakologii, Katedra Przedklinicznych Nauk Weterynaryjnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, u.Akademicka12, 20-033 Lublin

autor

Kowalski C. J.

• Zakład Farmakologii, Katedra Przedklinicznych Nauk Weterynaryjnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, u.Akademicka12, 20-033 Lublin

autor

Burmanczuk A.

• Zakład Farmakologii, Katedra Przedklinicznych Nauk Weterynaryjnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, u.Akademicka12, 20-033 Lublin

Bibliografia

• 1. Alstadhaug K. B., Odeh F., Salvesen R., Bekkelund S. I.: Prophylaxis of migraine with melatonin: A randomized controlled trial. Neurology 2010, 75, 1527-1532.
• 2. Ambritz-Tututi M., Grandos-Soto V.: Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 2007, 132, 273-280.
• 3. Arreola-Espino R., Urquiza-Marín H., Ambriz-Tututi M., Araiza-Saldaña C. I., Caram-Salas N. L., Rocha-González H. I., Mixcoatl-Zecuatl T., Granados-Soto V.: Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur. J. Pharmacol. 2007, 577, 203-210.
• 4. Ayar A., Duncan J. M., Ozcan M., Kelestimur H.: Melatonin inhibits high voltage activated calcium currents in cultured rat dorsal root ganglion neurons. Neurosci. Lett. 2001, 313, 73-77.
• 5. Browning C., Beresford I., Fraser N., Giles H.: Pharmacological characterization of human recombinant melatonin MT1 and MT2 receptors. Br. J. Pharmacol. 2000, 129, 877-886.
• 6. Brun J., Claustrat B., Saddier P., Chazot G.: Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses Cephalalgia 1995, 15, 136-139.
• 7. Brzeziński A.: Melatonin in humans. New Eng. J. Med. 1997, 336, 187-195.
• 8. Chuchuen U., Ebadi M., Govitrapong P.: The stimulatory effect of mu- and delta-opioid receptors on bovine pinealocyte melatonin synthesis. J. Pineal Res. 2004, 37, 223-229.
• 9. Citera G., Arias M. A., Maldonado-Cocco J. A., Lázaro M. A., Rosemffet M. G., Brusco L. I., Scheines E. J., Cardinalli D. P.: The effect of melatonin in patients with fibromyalgia: A pilot study. Clin. Rheumatol. 2000, 19, 9-13.
• 10. Claustrat B., Brun J., Geoffriau M., Zaidan R., Mallo C., Chazot G.: Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997, 17, 511-517.
• 11. Coto-Montes A., Masson-Pevet M., Pevet P., Moller M.: The presence of opioidergic pinealocytes in the pineal gland of the European hamster (Cricetus cricetus): an immunocytochemical study. Cell Tissue Res. 1994, 278, 483-491.
• 12. Cutando A., Arana C., Gomes-Moreno G., Escames G., Lopez A.: Local application of melatonin into alveolar socket of Beagle dogs reduces tooth removal – induced oxidative stress. J. Periodontol. 2007, 78, 576-583.
• 13. Cuzzocrea S., Costantino G., Mazzon E., Caputi A. P.: Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. J. Pineal Res. 1999, 27, 9-14.
• 14. El-Shenawy S. M., Abdel-Salam O. M. E., Baiuomy A. R., El-Batran S., Arbid M. S.: Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacol. Res. 2002, 46, 235-243.
• 15. Gagnier J. J.: The therapeutic potential of melatonin in migraines and other headache types. Altern. Med. Rev. 2001, 6, 383-389.
• 16. Gall C. von, Stehle J., Weaver D.: Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002, 309, 151-162.
• 17. García-Rodríguez L. A., Jick H.: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343, 769-772.
• 18. Govitrapong P., Sawlom S., Ebadi M.: The presence of delta and mu-, but not kappa or ORL1 receptors in bovine pinealocytes. Brain Res. 2002, 951, 23-30.
• 19. Hernández-Pacheco A., Araiza-Saldaña C. I., Granados-Soto V., Mixcoatl-Zecuatl T.: Possible participation of the nitric oxide-cyclic GMP-protein kinase G-K+ channels pathway in the peripheral antinociception of melatonin. Eur. J. Pharmacol. 2008, 596, 70-76.
• 20. Hussain S. A., Al-Khalifa I. I., Jasim N. A., Gorial F. I.: Adjuvant use of melatonin for treatment of fibromyalgia. J. Pineal Res. 2011, 50, 267-271.
• 21. Konturek S. J., Konturek P. C., Brzozowski T., Bubenik G. A.: Role of melatonin in upper gastrointestinal tract. J. Physiol. Pharmacol. 2007, 58 (Suppl. 6), 23-52.
• 22. Lakin M. L., Miller C. H., Stott M. L., Winters W. D.: Involvement of the pineal gland and melatonin in murine analgesia. Life Sci. 1981, 29, 2543-2551.
• 23. Li S. R., Wang T., Wang R., Dai X., Chen Q., Li R. D.: Melatonin enhances antinociceptive effects of δ-, but not μ-opioid agonist in mice. Brain Res. 2005, 1043, 132-138.
• 24. Lissoni P., Esposti D., Mauri R., Resentini M., Moravito F., Fumagali P., Santagostino A., Delitala G., Fraschini F.: A clinical study on the relationship between the pineal gland and the opioid system. J. Neural Transm. 1986, 65, 63-73.
• 25. Lu W. Z., Gwee K. A., Moochhalla S., Ho K. Y.: Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: A double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 2005, 22, 927-934.
• 26. Lutsch E. F., Morris R. W.: Light reversal of a morphine-induced analgesia susceptibility rhythm in mice. Experientia 1971, 27, 420-421.
• 27. Masruha M. R., de Souza Vieira D. S., Minett T. S. C., Cipolla-Neto J., Zukerman E., Vilanova L. C. P., Peres M. F. P.: Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J. Headache Pain 2008, 9, 221-224.
• 28. Mease P.: Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. J. Rheumatol. 2005, 32 (Suppl. 75), 6-21.
• 29. Morris R. W., Lutsch E. F.: Daily susceptibility rhythm to morphine analgesia. J. Pharm. Sci. 1969, 58, 374-376.
• 30. Mozaffari S., Rahimi R., Abdollahi M.: Implications of melatonin therapy in irritable bowel syndrome: A systematic review. Curr. Pharm. Des. 2010, 16, 3646-3655.
• 31. Naguib M., Hammond D. L., Schmid P. G., Baker M. T., Cutkomp J., Queral L., Smith T.: Pharmacological effects of intravenous melatonin: Comparative studies with thiopental and propofol. Br. J. Anaesth. 2003, 90, 504-507.
• 32. Noseda R., Hernández A., Valladares L., Mondaca M., Laurido C., Soto-Moyano R.: Melatonin-induced inhibition of spinal cord synaptic potentiation in rats is MT2 receptor-dependent. Neurosci. Lett. 2004, 360, 41-44.
• 33. Pang C. S., Tsang S. F., Yang J. C.: Effects of melatonin, morphine and diazepam on formalin-induced nociception in mice. Life Sci. 2001, 68, 943-951.
• 34. Pang S. F., Wan Q., Brown G. M.: Melatonin receptors in the spinal cord. Biol. Signals 1997, 6, 272-283.
• 35. Pasternak G. W.: When it comes to opiates, just say NO. J. Clin. Invest. 2007, 117, 3185-3187.
• 36. Peres M. F. P., Zukerman E., Da Cunha Tanuri F., Moreira F. R., Cipolla-Neto J.: Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004, 63, 757.
• 37. Prada C., Udin S. B.: Melatonin decreases calcium levels in retinotectal axons of Xenopus laevis by indirect activation of group III metabotropic glutamate receptors. Brain Res. 2005, 1053, 67-76.
• 38. Raghavendra V., Agrewala J. N., Kulkarni S. K.: Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice. Eur. J. Pharmacol. 2000, 395, 15-21.
• 39. Ray M., Mediratta P. K., Mahajan P., Sharma K. K.: Evaluation of the role of melatonin in formalin-induced pain response in mice. Indian J. Med. Sci. 2004, 58, 122-130.
• 40. Reiter R. J., Tan D. X., Manchester L. C., Gitto E., Fuentes-Broto L.: Gastrointestinal tract and melatonin: reducing pathophysiology. Gastroenterol. Polska 2010, 17, 213-218.
• 41. Rosenfeld J. P., Rice P. E.: Diurnal rhythms in nociceptive thresholds of rats. Physiol. Behav. 1979, 23, 419-420.
• 42. Saha L., Malhotra S., Rana S., Bhasin D., Pandhi P.: A preliminary study of melatonin in irritable bowel syndrome. J. Clin. Gastroenterol. 2007, 41, 29-32.
• 43. Shavali S., Begonia H., Govitrapong P., Sawlom S., Ajjimaporn A., Klongpanichapak S., Ebadi M.: Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain Res. Bull. 2005, 64, 471-478.
• 44. Song G. H., Leng P. H., Gwee K. A., Moochhala S. M., Ho K. Y.: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: A randomised, double blind, placebo controlled study. Gut 2005, 54, 1402-1407.
• 45. Stankov B., Biella G., Panara C., Lucini V., Capsoni S., Fauteck J., Cozzi B., Fraschini F.: Melatonin signal transduction and mechanism of action in the central nervous system: using the rabbit cortex as a model. Endocrinology 1992, 130, 2152-2159.
• 46. Stankov B., Cozzi B., Lucini V., Capsoni S., Fauteck J., Fumagalli P.: Localization and characterization of melatonin binding sites in the brain of rabbit (Oryctolagus cuniculus) by autoradiography and in vitro ligand-receptor binding. Neurosci. Lett. 1991, 131, 68-72.
• 47. Top M. Van Den, Buijs R. M., Ruiijter J. M., Delagrande P., Spanswick D., Hermes L. H.: Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurons in vitro independent of their circadian rhythm. Neuroscience 2001, 107, 99-108.
• 48. Ulugol A., Dokmeci D., Guray G., Sapolyo N., Ozyigit F., Tamer M.: Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: Possible involvements of the L-arginine-NO pathway and opioid system. Life Sci. 2006, 78, 1592-1597.
• 49. Vanecek J.: Cellular mechanisms of melatonin action. Physiol. Rev. 1998, 78, 687-721.
• 50. Vanecek J., Vollrath L.: Melatonin inhibits cyclic AMP and cyclic GMP accumulation in the rat pituitary. Brain Res. 1989, 505, 157-159.
• 51. Vanegas H., Schaible H.: Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 2000, 85, 9-18.
• 52. Vidor L. P., Torres I., Custodio de Souza I. C., Fregni F., Caumo W.: Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study. J. Pain Symptom Manage. 2012, (in press)
• 53. Vitte P. A., Harthe C., Lestage P., Claustrat B., Bobillier P.: Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. J. Pineal Res. 1988, 5, 437-453.
• 54. Wang T., Li S. R., Dai X., Peng Y., Chen Q., Wang R.: Effects of melatonin on orphanin FQ/nociceptin-induced hyperalgesia in mice. Brain Res. 2006, 1085, 43-48.
• 55. Wolf B. G., Weese J. L., Ludwig K. A., Delaney C. P., Stamos M. J., Michelassi F., Du W., Techner L.: Postoperative Ileus-Related Morbidity Profile in Patients Treated with Alvimopan after Bowel Resection. J. Am. Coll. Surg. 2007, 204, 609-616.
• 56. Woolf C. J.: Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med. 2004, 140, 441-451.
• 57. Xu S., Wei W., Shen Y., Hao J., Ding C.: Studies on the antiinflamatory, immunoregulatory, and analgesic actions of melatonin. Drug Dev. Res. 1996, 39, 167-173.
• 58. Yousaf F., Seet E., Venkatraghavan L., Abrishami A., Chung F.: Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: A qualitative systematic review of randomized trials. Anesthesiology 2010, 113, 968-976.
• 59. Yu C. X., Wu G. C., Xu S. F., Chen C. H.: Effect of melatonin on release of endogenous opioid peptides in rat periaqueductal gray. Sheng Li Xue Bao 2000, 52, 207-210.
• 60. Yu C. X., Zhu C. B., Xu S. F., Cao X. D., Wu G. C.: Selective MT2 melatonin receptor antagonist blocks melatonin-induced antinociception in rats. Neurosci. Lett. 2000, 282, 161-164.
• 61. Yu C. X., Zhu C.-B., Xu S. F., Cao X. D., Wu G. C.: The analgesic effects of peripheral and central administration of melatonin in rats. Eur. J. Pharmacol. 2000, 403, 49-53.